Longevity Science Foundation Launches Decentralised Blockchain Voting Programme
The Longevity Science Foundation (LSF) — a Swiss non-profit dedicated to advancing the healthy human lifespan — has announced today it will use blockchain technology in its funding selection process. To do so, the Foundation has created LSF Points, which will be distributed to all Foundation donators. These non-monetary tokens will empower them to vote on which projects and proposals they believe should be funded by the Foundation. All projects under consideration will first be chosen by the LSF Visionary Board for technical soundness, impact, and scientific quality. The executive summary of the programme can be found here.
“Beyond having a credible, strict and transparent evaluation and selection process, the LSF wishes to accommodate a system for donors to also express their opinion and vote for their favourites among the applications,” Visionary Board Chairman Evelyne Yehudit Bischof said. “This programme will not only encourage donor involvement but will also help us achieve our mission of bringing more longevity-based solutions to a wider audience within the next five years.”
The LSF Points are not an investment instrument and do not have any monetary value. The LSF does not sell nor exchange LSF Points to any currency–they are strictly an instrument for internal decision-making and governance. However, in addition to votes, donors can use points to earn rewards such as NFTs commemorating contributions, consultations with longevity specialists, and early access to treatments. Point transfers and report security will be managed via a smart contract on an Ethereum-based public blockchain.
“We aim to maintain full transparency while reducing bureaucratic burden in the funding process,” Bischof said. “Every funding decision the Foundation makes is fully auditable applying the new blockchain programme, which guarantees transparency around LSF work.”
After receiving funding proposals, a team of longevity opinion leaders pre-vets and shortlists selected proposals and defines priority vectors to deliver a comprehensive set of funding targets. These are reviewed by donors who then execute their voting rights through their holding of LSF Points. Details of the process can be found on the website.
The Foundation is seeking to fund projects that can facilitate and accelerate significant progress in longevity medicine as soon as possible. The Foundation’s Visionary Board is composed of leading longevity researchers like Bischof, Andrea B. Maier, Eric Verdin, Matt Kaeberlein, Michael Levitt, and Alex Zhavoronkov.
About the Longevity Science Foundation
The Longevity Science Foundation is a Swiss nonprofit organisation advancing human longevity by funding research and development of medical technologies to extend the healthy human lifespan. The long-term mission of the Longevity Science Foundation is to help make longevity-focused care accessible to everyone, no matter their background, by bringing cutting-edge science on aging out of the laboratory and into the mainstream. To learn more, visit www.longevity.foundation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005117/en/
Contact information
Rachel Pipan
press@longevity.foundation
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)17.9.2025 22:46:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commission’s approval of vimseltinib for TGCT is a significant milestone for Deciphera, ONO, and TGCT patients across the European Union who are in need of a non-invasive treatment option. We are excited to leverage our global commercial infrastructure to bring vimseltinib to these patients,” said Ryota Udagawa, President and Chief Executive Officer of Deciphera. “We look forward to working with health authorities to ensure all eligible patients who can benefit from vimseltinib have access as quickly as p
Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder17.9.2025 19:09:00 EEST | Press release
Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909723150/en/ Global Appeal Post-pandemic travellers prioritize remote, nature-led adventures and privacy-forward itineraries [1][3]. Adventure tourism is on a sharp upswing globally [5], while research highlights how social media and influencer content accelerate demand for marquee mountain experiences [7]. At the same time, heli-sports are forecast to expand steadily across Canada, Europe, APAC, and South America [8]. World’s Best Heli-Ski NEH operates in BC’s Ske
Bacardi Announces Internal Leadership Moves Within People and Supply Chain Organizations17.9.2025 17:35:00 EEST | Press release
Bacardi Limited, the world’s largest privately held international spirits company, announces several internal moves, underscoring the company’s global approach to leadership development and a commitment to talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917778482/en/ Bacardi announces new roles for Dave Ingram and Nicole Zukowski. Dave Ingram has been appointed to the role of Chief People & Business Transformation Officer, responsible for delivering the next chapter for building an organization that is fit for the future. In this role, Dave will continue to prioritize talent management, succession planning, performance management, and capability building which are core to setting a legacy of more than 163 years for the success of generations to come. Dave, a member of the Bacardi Global Leadership Team, most recently served as Chief Supply Chain Officer, where he led the end-to-end supply chain for the company’s po
Andersen Consulting Adds Collaborating Firm Charter17.9.2025 16:30:00 EEST | Press release
Andersen Consulting expands its digital transformation capabilities through a Collaboration Agreement with Charter, a Canadian consulting firm that specializes in IT strategy, managed services, and application delivery. Established in 1997, Charter delivers technology projects with a business-first mindset and deep technical expertise, offering IT advisory, cloud infrastructure, cybersecurity, application development, project delivery, and business architecture. Charter supports traditional enterprise, government, service provider, and mid-market clients with implementation, network infrastructure, and customer-facing applications—delivered through a lifecycle approach from strategy to execution. “Our goal at Charter has always been to remove the complexity from IT and help organizations move with confidence,” said Kelly Michell, president of Charter. “Our collaboration with Andersen Consulting enables us to bring our integrated, business-aligned solutions to new markets and continue d
Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 16:10:00 EEST | Press release
Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed Since May 2025 Delivered with Wildix reseller Focus CX, the rollout shows how agentic voice automation relieves frontline pressure, improves patient experience and provides measurable value. Missed calls remain one of healthcare’s hidden drains. Over a third of new patient calls go unanswered and most never c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom